NCT00671424View on ClinicalTrials.gov

A Study To Compare Effects Of GSK189075 In Combination With Either Furosemide Or Hydrochlorothiazide

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2008

Conditions
Type 2 Diabetes MellitusDiabetes Mellitus, Type 2
Interventions
DRUG

Hydrochlorothiazide (HCTZ)

DRUG

Remogliflozin etabonate (GSK189075)

DRUG

Furosemide

Trial Locations (1)

43212

GSK Investigational Site, Columbus

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY